Keynote Panel Discussion – Driving Clinical Success in Solid Tumor Settings

Time: 10:00 am
day: Day One


  • What is the optimal cell type to tackle the solid tumor microenvironment
  • What solid tumors should the field be targeting first, considering myeloid compartments and heterogeneity?
  • Address acquired versus inherent resistance to immunotherapy
  • Discuss how different modalities induce epitope spreading and the potential of this to overcome heterogeneity